Comparison between an Iranian Traditional Medicine pharmaceutical product and fatty substance on reduction of liver and gallbladder disturbing shadow in myocardial perfusion imaging
Phase 2
- Conditions
- Ischaemic heart diseases.Atherosclerotic heart disease
- Registration Number
- IRCT2016071215860N4
- Lead Sponsor
- Tehran University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients who refer by cardiologists to Nuclear medicine center of Imam Khomeini hospital for performing perfusion scan; patients between 18 to 70 years; Hyperlipidemic patients; Unwillingness to use fat; Feeling of nausea when patients eat fat
Exclusion criteria: Patients who suffer from certain diseases such as heart disease or liver and bile ducts disorders; Pregnancy; Known active infection; An identified blood laboratory abnormalities at baseline; Peptic ulcer or biliary obstruction or gallstones
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount of clearing the intrusive activity of the liver. Timepoint: 30 and 60 and 90 minutes after administering radioactive substance. Method of measurement: Measuring Heart/Liver ratio by observation and ratio determination of numeration of the heart to the liver.;Amount of clearing the intrusive activity of the gallbladder. Timepoint: 30 and 60 and 90 minutes after administering radioactive substance. Method of measurement: easuring Heart/gallbladder ratio.
- Secondary Outcome Measures
Name Time Method